NEUCHÂTEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision annuncia nuova evidenza clinica che conferma le eccezionali prestazioni della sua lente intraoculare (IOL) Lucidis®, rafforzando la sua posizione come soluzione innovativa nella chirurgia dell…
Category: Business
Lucidis® estabelece padrões elevados na cirurgia de catarata premium com desempenho visual completo
NEUCHÂTEL, Suíça–(BUSINESS WIRE)–A Swiss Advanced Vision anuncia novas evidências clínicas que confirmam o desempenho excepcional de sua lente intraocular (LIO) Lucidis®, fortalecendo sua posição como uma solução inovadora na cirurgia de catarata pre…
Samenvatting: Lucidis® stelt hoge normen voor hoogwaardige cataractchirurgie met volledig gezichtsvermogen
NEUCHÂTEL, Zwitserland–(BUSINESS WIRE)–Swiss Advanced Vision maakt nieuwe klinische resultaten bekend die de uitzonderlijke prestaties van zijn Lucidis® intraoculaire lens (IOL) bevestigen, waardoor zijn positie als baanbrekende oplossing in hoogwaar…
Lucidis®憑藉全視程視覺表現，為頂級白內障手術樹立高標準
瑞士紐沙特–(BUSINESS WIRE)–(美國商業資訊)– Swiss Advanced Vision公布最新臨床證據，證實其Lucidis®人工水晶體(IOL)表現卓越，進一步鞏固其頂級白內障手術顛覆性解決方案的地位。與傳統的景深擴展型(EDOF)人工水晶體不同，Lucidis®可提供媲美頂級三焦點IOL的全視程視覺表現，同時保留對比敏感度、視覺品質，並將光暈和眩光等副作用降至最低，這也是其專利全折射式設計的代表性特徵。 近期一項經同儕審查的研究——由H. Naftali、W. Nass…
スイス・アドバンスト・ビジョン、Lucidis®でフルレンジの視力でプレミアム白内障手術の高い業界標準を確立
ヌーシャテル（スイス）–(BUSINESS WIRE)–（ビジネスワイヤ） — スイス・アドバンスト・ビジョン（SAV-IOL）は、Lucidis®眼内レンズ（IOL）の卓越した性能を裏付ける新たな臨床エビデンスを発表し、プレミアム白内障手術における革新的なソリューションプロバイダーとしての地位をさらに強化しました。従来の拡張焦点深度レンズとは異なり、Lucidis®は、プレミアム三焦点IOLに匹敵するフルレンジの視力性能を実現しつつ、コントラスト感度と視力の質を維持し、特許取得済みの完全屈折…
Lucidis® setzt mit seiner umfassenden Sehleistung neue Maßstäbe in der Premium-Kataraktchirurgie
NEUCHÂTEL, Schweiz–(BUSINESS WIRE)–Swiss Advanced Vision gibt neue klinische Erkenntnisse bekannt, die die außergewöhnliche Leistungsfähigkeit seiner Lucidis®-Intraokularlinse (IOL) bestätigen und seine Position als bahnbrechende Lösung in der Premiu…
Lucidis® redefine los estándares de la cirugía de catarata prémium con una visión de rango completo
NEUCHÂTEL, Suiza–(BUSINESS WIRE)–Swiss Advanced Vision presentó nuevos datos clínicos que confirman el desempeño sobresaliente de su lente intraocular (LIO) Lucidis®, lo que consolida su lugar como una alternativa innovadora en la cirugía de catarata…
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance
NEUCHÂTEL, Switzerland–(BUSINESS WIRE)– #CataractSurgery–Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances.
RevolutionEHR Launches RevPay, Redefining How Optometry Practices Manage Cash Flow
SAN DIEGO–(BUSINESS WIRE)– #DigitalPayments–RevolutionEHR, the market-leading optometry-first operating platform, today announced the launch of RevPay, its fully embedded payments solution designed to help practices get paid effortlessly while recov…
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Col…
Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
GENEVA–(BUSINESS WIRE)–Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
GENEVA–(BUSINESS WIRE)–Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative re…
NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis
MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration…
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity
Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
GENEVA–(BUSINESS WIRE)–Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
Optometry Practices Elevate Patient Experience with RevolutionEHR’s Integrated, Modernized Patient Portal
SAN DIEGO–(BUSINESS WIRE)– #ONCCompliant–RevolutionEHR launches a modern, compliance-first patient portal that streamlines scheduling, billing, messaging, and records for optometry practices.
Warby Parker to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be releas…
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that the first patient has been dosed in t…
Warby Parker Appoints Adrian Mitchell as Chief Financial Officer
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment stren…